Head And Neck Cancer
Interventions reduce opioid prescribing after neck dissection for thyroid cancer
DALLAS — Preoperative counseling and perioperative pain management strategies significantly reduced opioid prescriptions at discharge for patients who underwent lateral neck dissection for thyroid cancer, according to study results.
Factors predict survival after immunotherapy combination for HNSCC
DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.
Neoadjuvant pembrolizumab does not increase surgical complications in oral cavity cancer
DALLAS — Neoadjuvant pembrolizumab did not increase risk for serious surgical complications among patients with advanced oral cavity cancer, study results presented at American Head & Neck Society Annual Meeting showed.
Immunotherapy before head and neck cancer surgery does not increase complications
DALLAS — Neoadjuvant immunotherapy did not increase risk for complications among patients who underwent surgery for head and neck cancers, according to study results presented at American Head & Neck Society Annual Meeting.
Tislelizumab regimen confers clinically meaningful PFS benefit in nasopharyngeal cancer
The addition of tislelizumab to chemotherapy conferred a clinically meaningful PFS benefit among patients with recurrent or metastatic nasopharyngeal cancer, according to updated results of the randomized phase 3 RATIONALE-309 study.
Bispecific antibody shows durable benefit in advanced solid tumors
A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.
Research spotlight: Innovative strategies guide head and neck cancer treatment
April is Head and Neck Cancer Awareness Month.
Immunotherapy safe within 90 days of radiation therapy for patients with cancer
Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.
Thyroidectomy without radioiodine noninferior for patients with low-risk thyroid cancer
A follow-up strategy without radioiodine appeared noninferior to an ablation strategy with radioiodine among patients with low-risk thyroid cancer undergoing thyroidectomy, according to study results in The New England Journal of Medicine.
AI platform predicts thyroid cancer, pathologic stage, BRAF status using ultrasound images
An artificial intelligence platform predicted thyroid cancer with high accuracy based on analysis of routine ultrasound images, according to study results presented at Multidisciplinary Head and Neck Cancers Symposium.